Filtered By:
Source: Journal of Stroke and Cerebrovascular Diseases
Condition: Thrombosis
Drug: Warfarin
This page shows you your search results in order of date.
Order by Relevance | Date
Total 17 results found since Jan 2013.
Clinical Trial Based Rationale for the Successful Use of DOAC in the Treatment of Cerebral Venous Sinus Thrombosis (CVST): A Case Report
In cerebral venous sinus thrombosis (CVST), venous sinus occlusion increases venous pressure and disrupts venous return, resulting in progression to venous infarction and venous hemorrhage, with poor neurologic outcome. Therefore, early recanalization of the major venous sinus is critical.Anticoagulant therapy with continuous intravenous infusion of heparin and subsequent oral anticoagulant administration is the recommended first line of treatment for CVST. Some large clinical trials for venous thromboembolism (VTE) have shown that direct oral anticoagulant (DOAC) is non-inferior to the standard therapy with heparin or war...
Source: Journal of Stroke and Cerebrovascular Diseases - September 3, 2020 Category: Neurology Authors: Toshiaki Bando, Yasushi Ueno, Daisuke Shimo, Takahiro Kuroyama, Kazuyuki Mikami, Shinya Hori, Osamu Hirai Tags: Case Report Source Type: research
Reversal strategies and outcomes in patients with atrial fibrillation and warfarin-associated intracranial hemorrhage
While anticoagulants are highly effective in preventing thromboembolism in atrial fibrillation (AF), they raise the risk of hemorrhage, which can be life-threatening especially in cases of intracranial hemorrhage (ICH). Warfarin-associated intraparenchymal hemorrhage (IPH) leads to death within 30 days in as many as 60% of cases while the other major category of ICH on warfarin, subdural hemorrhage (SDH), leads to death in approximately a quarter of cases.1 Managing these potentially devastating bleeds is an important consideration in treating patients on oral anticoagulant therapy.
Source: Journal of Stroke and Cerebrovascular Diseases - July 15, 2020 Category: Neurology Authors: Daniel E. Singer, Leila H. Borowsky, Susan Regan, Jong Woo Lee, Kristina Zint, Lionel Riou Franca, Joshua N. Goldstein Source Type: research
Multicenter prospective analysis of stroke patients taking oral anticoagulants: The PASTA registry - Study design and characteristics
The management of atrial fibrillation and deep venous thrombosis has evolved with the development of direct oral anticoagulants (DOAC), and oral anticoagulant (OAC) might influence the development or clinical course in both ischemic and hemorrhagic stroke. However, detailed data on the differences between the effects of the prior prescription of warfarin and DOAC on the clinical characteristics, neuroradiologic findings, and outcome of stroke are limited.
Source: Journal of Stroke and Cerebrovascular Diseases - October 28, 2019 Category: Neurology Authors: Satoshi Suda, Yasuyuki Iguchi, Shigeru Fujimoto, Yoshiki Yagita, Yu Kono, Masayuki Ueda, Kenichi Todo, Tomoyuki Kono, Takayuki Mizunari, Mineo Yamazaki, Takao Kanzawa, Seiji Okubo, Kimito Kondo, Nobuhito Nakajima, Takeshi Inoue, Takeshi Iwanaga, Makoto Na Source Type: research
Intracardiac Thrombus Following Rivaroxaban Treatment in a Patient with Atrial Fibrillation Associated with Rheumatic Heart Disease
We report a case of atrial fibrillation with rheumatic heart disease (RHD) who had intracardiac thrombus and cardiogenic cerebral embolism with rivaroxaban therapy. Intracardiac thrombus disappeared after switching from rivaroxaban to warfarin. Patients of RHD have the possibility of gradual progression of valvular disease even if they are old, so we need to distinguish nonvalvular atrial fibrillation from RHD before starting direct oral anticoagulants.
Source: Journal of Stroke and Cerebrovascular Diseases - August 15, 2019 Category: Neurology Authors: Hiroaki Ohara, Shiro Yamamoto, Keiko Nagano, Kazuo Hashikawa Tags: Case Report Source Type: research
Is Rivaroxaban a Safe Choice for Apical Thrombus in Atrial Fibrillation Patients? A Case Report
Left ventricular thrombi are mostly seen in the akinetic segments of left ventricle and warfarin is the golden standard treatment. In our case, a 67-year-old male patient with ischemic dilated cardiomyopathy and atrial fibrillation was under warfarin treatment, but due to fluctuations in international normalized ratio, warfarin was discontinued and changed to rivaroxaban (20 mg once a day). He had a fixed thrombus measuring 1.80 × 1.12 cm2 in the left ventricle under warfarin treatment before rivaroxaban use.
Source: Journal of Stroke and Cerebrovascular Diseases - May 4, 2018 Category: Neurology Authors: Fatih Aydin, Ozge Turgay Yildirim, Ayse Huseyinoglu Aydin, Evrin Dagtekin, Ercan Aksit Tags: Case Studies Source Type: research
Bilateral Cerebral Infarctions and Intracardiac Thrombus in a Young Duchenne Muscular Dystrophy Patient
A 31-year-old man with Duchenne muscular dystrophy was admitted to our center, having infarctions in bilateral cerebral hemispheres and an occluded right middle cerebral artery. His right middle cerebral artery was spontaneous recanalization on the next day, and thrombus in the left ventricle vanished on the eighth day after giving warfarin.
Source: Journal of Stroke and Cerebrovascular Diseases - March 20, 2018 Category: Neurology Authors: Yanan Qiao, Manabu Inoue, Muneaki Kikuno, Dantao Peng, Zunjing Liu, Kazunori Toyoda Tags: Case Studies Source Type: research
Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation
Warfarin has a narrow therapeutic window. We hypothesized that genetic factors related to warfarin metabolism (CYP2C9) and activity (VKORC1) would show stronger associations than modifiable factors with the quality of anticoagulation control and risks for thromboembolism and hemorrhage.
Source: Journal of Stroke and Cerebrovascular Diseases - April 13, 2017 Category: Neurology Authors: Yun Kyung Park, Mi Ji Lee, Jae Ha Kim, Jin Soo Lee, Rae Woong Park, Gyeong-Moon Kim, Chin-Sang Chung, Kwang Ho Lee, June Soo Kim, Soo-Youn Lee, Oh Young Bang Source Type: research
Warfarin-Resistant Deep Vein Thrombosis during the Treatment of Acute Ischemic Stroke in Lung Adenocarcinoma
A 66-year-old man with acute ischemic stroke in the setting of lung adenocarcinoma developed acute-onset deep vein thrombosis (DVT) of the lower limbs after changing to warfarin from a heparin combination. The diagnosis of warfarin-resistant DVT was established based on the laboratory data and clinical evaluation. Heparin administration resulted in good control of thrombin regulation. Cancer patients are at high risk of venous thromboembolism, and the combination of these 2 conditions is known as Trousseau's syndrome.
Source: Journal of Stroke and Cerebrovascular Diseases - June 21, 2016 Category: Neurology Authors: Hiroyuki Naito, Shiro Aoki, Naoko Sumi, Kazuhide Ochi, Naohisa Hosomi, Hirofumi Maruyama, Masayasu Matsumoto Tags: Case Studies Source Type: research
Secondary Prevention of Stroke with Warfarin in Patients with Nonvalvular Atrial Fibrillation: Subanalysis of the J-RHYTHM Registry
Prior ischemic stroke or transient ischemic attack (TIA) is a high risk for thromboembolism in patients with nonvalvular atrial fibrillation (NVAF). To clarify rates of thromboembolic and hemorrhagic events, and target intensities of warfarin for secondary prevention, a subanalysis was performed using data from the J-RHYTHM Registry.
Source: Journal of Stroke and Cerebrovascular Diseases - December 22, 2015 Category: Neurology Authors: Eitaro Kodani, Hirotsugu Atarashi, Hiroshi Inoue, Ken Okumura, Takeshi Yamashita, Hideki Origasa, J-RHYTHM Registry Investigators Source Type: research
Efficacy and Safety of Edoxaban in Nonvalvular Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials
This study compared the efficacy and safety of edoxaban and warfarin in nonvalvular atrial fibrillation, and the effects of different edoxaban dosages. Methods: A systematic search for randomized controlled trials comparing edoxaban with warfarin in nonvalvular atrial fibrillation was conducted using PubMed, EMBASE, and the Cochrane Library databases.
Source: Journal of Stroke and Cerebrovascular Diseases - August 28, 2015 Category: Neurology Authors: Junyu Chen, Xiaodong Zhuang, Ming Long, Chen Su, Lichun Wang Source Type: research
Embolic Stroke during Apixaban Therapy for Left Atrial Appendage Thrombus
Left atrial appendage (LAA) thrombus is associated with atrial fibrillation (AF) and is a powerful predictor of cardiogenic thromboembolism. Warfarin is an established anticoagulant therapy for patients with LAA thrombus to prevent thromboembolic complications. Apixaban is superior to warfarin in the prevention of thromboembolic complications in patients with AF, and there are case reports showing apixaban-associated resolution of LAA thrombus; however, the efficacy and safety of apixaban for the treatment of LAA thrombus remains unproven.
Source: Journal of Stroke and Cerebrovascular Diseases - January 22, 2015 Category: Neurology Authors: Masaki Ohyagi, Kazuha Nakamura, Mutsufusa Watanabe, Hiroto Fujigasaki Tags: Case Report Source Type: research
Prothrombin Complex Concentrate (Beriplex P/N)–related Renal and Cerebral Infarctions in a Patient with Warfarin-associated Intracerebral Hemorrhage
A 45-year-old man receiving warfarin treatment suffered from an intracerebral hemorrhage. Four-factor prothrombin complex concentrate (PCC) was administered to correct coagulopathy. However, bilateral renal infarcts and a cerebral infarct developed on day 5 and 7, respectively after PCC administration. Although the occurrence of PCC-related thromboembolism is low, health care practitioners should closely follow-up the symptoms and signs of thrombosis after PCC administration.
Source: Journal of Stroke and Cerebrovascular Diseases - October 2, 2014 Category: Neurology Authors: Shin-Yi Lin, Sun-Chun Tang, Li-Jiuan Shen, Jiann-Shing Jeng Tags: Case Report Source Type: research
Reduced Smoke-like Echo and Resolved Thrombus in the Left Atrium with Rivaroxaban Therapy in an Acute Cardioembolic Stroke Patient
We report a case of a nonvalvular atrial fibrillation (NVAF) patient with acute cardioembolic stroke in whom rivaroxaban, an oral direct factor Xa inhibitor, reduced a smoke-like echo in the left atrium and resolved a thrombus in the left atrial appendage. A 71-year-old man was admitted because of the sudden onset of right hemiplegia and aphasia and was diagnosed with acute cardioembolic stroke associated with NVAF. The patient had not been treated with warfarin before admission, and rivaroxaban therapy (15 mg once daily) was initiated. Transesophageal echocardiography was performed on day 8 and a mobile thrombus was foun...
Source: Journal of Stroke and Cerebrovascular Diseases - April 11, 2014 Category: Neurology Authors: Shin Saito, Hirofumi Tomita, Yoshihiro Kimura, Hiroshi Shiroto, Joji Hagii, Norifumi Metoki, Hiroyasu Hitomi, Takaatsu Kamada, Tomohiro Osanai, Ken Okumura, Minoru Yasujima Tags: Case Reports Source Type: research
